

(<https://www.medtronic.com/men/index.html>)



## Resolute Onyx DES

[for coronary artery disease](#)

Resolute Onyx™ is a drug-eluting stent (DES) that's different by design, optimised for complex PCI, and proven safe and effective in real-world, high bleeding risk patients on 1-month dual antiplatelet therapy (DAPT).<sup>1</sup>

DOWNLOAD BROCHURE(OPENS NEW WINDOW) (/CONTENT/DAM/MEDTRONIC-COM/XD-EN/HCP/DOCUMENTS/DIGITALHUB/CARDIOVASCULAR/CORONARY/CORONARY-STENTS/RESOLUTE-ONYX-PRODUCT-BROCHURE.PDF)

## OVERVIEW

Resolute Onyx DES is different by design to address your DES needs and a wide range of patient anatomies. It features:

- Best-in-class deliverability<sup>2</sup>
- Enhanced visibility with thinner struts<sup>2</sup>
- Smooth side branch access<sup>2</sup>
- Fast healing<sup>3</sup>
- The broadest diameter range

## PRODUCT FEATURES

### Best-in-class deliverability

### Single-wire design

Resolute Onyx DES is made from a single wire, which gives it a fluid range of motion and provides the flexibility needed for best-in-class deliverability.<sup>2</sup>

**Sinusoid-formed wire**

**Helical wrap**

**Laser-fused**

## **Competitive comparison**

Resolute Onyx DES is more deliverable than laser-cut SYNERGY™\* XD and XIENCE Skypoint™\*, which are stiffer.

### **Deliverability comparison – 3.0 mm DES<sup>2</sup>**

(Lower is better)

---

## **THE ONLY DES DESIGNED FROM A SINGLE WIRE<sup>‡</sup>**

Proven components for optimal healing

Watch a short video to learn more about the BioLinx™ polymer.



- Single-wire design provides a fluid range of motion and the conformability needed for superior strut apposition.<sup>2</sup>
- BioLinx biocompatible polymer provides superior thromboresistance.<sup>4</sup>
- When combined, fast healing occurs as evidenced by nearly 90% strut coverage at 30 days,<sup>3</sup> providing the foundation for the Onyx ONE Global Trial.
- The Onyx ONE Global Trial analysed real-world, high bleeding risk patients on 1-month DAPT treated with a Resolute Onyx DES or a BioFreedom™\* DCS.

- Results showed Resolute Onyx DES was safe and effective,<sup>1</sup> providing the option to shorten DAPT in patients who are at high bleeding risk.
- Based on these results, Resolute Onyx DES was the first DES CE-indicated for HBR patients on 1-month DAPT.

SEE THE ONYX ONE DATA ([HTTPS://WWW.MEDTRONIC.COM/ME-EN/HEALTHCARE-PROFESSIONALS/PRODUCTS/CARDIOVASCULAR/STENTS/RESOLUTE-ONYX-DES/CLINICAL-EVIDENCE.HTML](https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/clinical-evidence.html))

---

## Enhanced visibility with thinner struts

Platinum-iridium core within Resolute Onyx DES increases visibility for accurate stent placement without compromising strut thickness.<sup>2</sup>

### Average visibility comparison<sup>2</sup>

(Higher is better)

1. Cobalt alloy shell
2. Platinum iridium core

Resolute Onyx cobalt alloy shell and platinum-iridium core

---

## Smooth side branch access

Resolute Onyx DES has round struts to create a smooth passage when accessing the side branch and lower the propensity to catch during bifurcation procedures.<sup>2</sup>

### Strut comparison

#### Rounded strut cross-section

1. Resolute Onyx DES

## Square strut cross-section

- 1. SYNERGY™\* DES
- 2. XIENCE™\* DES

## Broadest diameter range

- Complex PCI requires a broad DES size matrix to match a wide range of patient anatomies.
- Resolute Onyx is the only DES with diameters ranging from 2.0 mm to 5.0 mm to treat a broad range of coronary vessel sizes.

Diameter (mm)	Stent Length (mm)									Maximum Expansion Capabilities (MSID†) (mm)
2.00	8	12	15	18	22	26	30	—	—	3.50‡
2.25	8	12	15	18	22	26	30	34	38	3.50‡
2.50	8	12	15	18	22	26	30	34	38	3.50‡
2.75	8	12	15	18	22	26	30	34	38	4.00‡
3.00	8	12	15	18	22	26	30	34	38	4.00‡
3.50	8	12	15	18	22	26	30	34	38	5.00‡
4.00	8	12	15	18	22	26	30	34	38	5.00‡
4.50	—	12	15	18	22	26	30	—	—	6.00‡
5.00	—	12	15	18	22	26	30	—	—	6.00‡

## PRODUCT DETAILS

8	2.00
12	RONYX20008X
15	RONYX20012X
18	RONYX20015X
22	RONYX20018X
26	RONYX20022X
30	RONYX20026X
34	RONYX20030X
38	<b>Stent Length (mm)</b>  N/A
N/A	

8	2.25
12	RONYX22508X
15	RONYX22512X
18	RONYX22515X
22	RONYX22518X
26	RONYX22522X
30	RONYX22526X
34	RONYX22530X
38	<div>Stent Length (mm)  RONYX22534X</div>
RONYX22538X	

8	2.50
12	RONYX25008X
15	RONYX25012X
18	RONYX25015X
22	RONYX25018X
26	RONYX25022X
30	RONYX25026X
34	RONYX25030X
38	<div>Stent Length (mm)  RONYX25034X</div>
RONYX25038X	

8	2.75
12	RONYX27508X
15	RONYX27512X
18	RONYX27515X
22	RONYX27518X
26	RONYX27522X
30	RONYX27526X
34	RONYX27530X
38	<b>Stent Length (mm)</b>  RONYX27534X
RONYX27538X	



8	3.00
12	RONYX30008X
15	RONYX30012X
18	RONYX30015X
22	RONYX30018X
26	RONYX30022X
30	RONYX30026X
34	RONYX30030X
38	<b>Stent Length (mm)</b>  RONYX30034X
RONYX30038X	

8	3.50
12	RONYX35008X
15	RONYX35012X
18	RONYX35015X
22	RONYX35015X
26	RONYX35022X
30	RONYX35026X
34	RONYX35030X
38	<div>Stent Length (mm)  RONYX35034X</div>
RONYX35038X	

8	4.00
12	RONYX40008X
15	RONYX40012X
18	RONYX40015X
22	RONYX40018X
26	RONYX40022X
30	RONYX40026X
34	RONYX40030X
38	<b>Stent Length (mm)</b>  RONYX40034X
RONYX40038X	

8	4.50
12	N/A
15	RONYX45012X
18	RONYX45015X
22	RONYX45018X
26	RONYX45022X
30	RONYX45026X
34	RONYX45030X
38	<b>Stent Length (mm)</b>  N/A
N/A	

<b>8</b>	<b>5.00</b>
<b>12</b>	N/A
<b>15</b>	RONYX50012X
<b>18</b>	RONYX50015X
<b>22</b>	RONYX50018X
<b>26</b>	RONYX50022X
<b>30</b>	RONYX50026X
<b>34</b>	RONYX50030X
<b>38</b>	<b>Stent Length (mm)</b>  N/A
N/A	

## Maximum expansion capabilities

For reference only in markets where the Resolute Onyx coronary stent and the 0.25 mm expansion have been approved.

## ADDITIONAL RESOURCES

### Onyx ONE Global Trial

First randomised, 1-month DAPT trial comparing a DES to a DES in ~2000 high bleeding risk patients on 1-month DAPT.

Review the Data (<https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/clinical-evidence.html>)

### Resolute Onyx DES is optimised for complex PCI

Resolute Onyx DES design exclusives make it ideal for complex cases.

See How (<https://www.medtronic.com/me-en/healthcare-professionals/products/cardiovascular/stents/resolute-onyx-des/complex-lesions.html>)

## Bifurcation education

View five techniques that highlight Resolute Onyx DES through endoscopic imaging captured inside an isolated and reanimated beating porcine heart.

Visit and Bookmark **(opens new window)** ([/content/dam/medtronic-com/global/HCP/elearning/bifurcation-exploration/backup/story\\_html5.html](/content/dam/medtronic-com/global/HCP/elearning/bifurcation-exploration/backup/story_html5.html))

---

The Resolute Onyx DES zotarolimus drug effectively inhibits neointimal growth while the exclusive, highly biocompatible BioLinx™ polymer contributes to minimal inflammation, low thrombotic risk,<sup>5</sup> as well as rapid, complete, and functional endothelial healing.<sup>§4</sup>



### **Onyx One Results Brochure** (.pdf) (opens new window)

([/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/UC202005505ML\\_Onyx\\_ONE\\_Results\\_Brochure.pdf?bypassIM=true](/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/UC202005505ML_Onyx_ONE_Results_Brochure.pdf?bypassIM=true))

This brochure presents clinical evidence about Onyx One.

307KB

(opens new window) ([/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/UC202005505ML\\_Onyx\\_ONE\\_Results\\_Brochure.pdf?bypassIM=true](/content/dam/medtronic-com/xd-en/hcp/documents/digitalhub/cardiovascular/coronary/coronary-stents/UC202005505ML_Onyx_ONE_Results_Brochure.pdf?bypassIM=true))

## Request more information

[Contact us \(/me-en/about/contact-us.html?src=cardiovascular.html\)](/me-en/about/contact-us.html?src=cardiovascular.html)

---

\*

As per April 2021.

†

Medtronic and Medtronic logo are trademarks of Medtronic. Third-party trademarks ("™†") belong to their respective owners. All other brands are trademarks of a Medtronic entity.

‡

Including Resolute Integrity™ DES, part of the Medtronic DES portfolio.

§

In porcine models.

---

# References

1

Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. *N Engl J Med*. March 26, 2020;382(13):1208-1218.

2

Based on bench test data on file at Medtronic. May not be indicative of clinical performance.

3

Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. *Adv Interv Cardiol*. 2019;15(2):143-150.

4

Jinnouchi H, Sato Y, Cheng Q, et al. *Int J Cardiol*. March 2021;327:52-57.



(mailto:?



body=https%3A%2F%2Fwww.me  
dtronic.com%2Fme-  
en%2Fhealthcare-  
professionals%2Fproducts%2Fca  
rdiovascular%2Fstents%2Fresolu  
te-onyx-des.html)



---

## PATIENTS AND CAREGIVERS

Overview (<https://www.medtronic.com/me-en/your-health.html>)

## HEALTHCARE PROFESSIONALS

Overview (<https://www.medtronic.com/me-en/healthcare-professionals.html>)

## OUR COMPANY

Key facts (<https://www.medtronic.com/me-en/our-company/key-facts.html>)

Leadership (<https://www.medtronic.com/me-en/our-company/leadership.html>)

Mission (<https://www.medtronic.com/me-en/our-company/mission.html>)

Career Opportunities (</me-en/about/careers.html>)

[Locations \(https://www.medtronic.com/me-en/our-company/locations.html\)](https://www.medtronic.com/me-en/our-company/locations.html)

## **OUR IMPACT**

[Overview \(https://www.medtronic.com/me-en/our-impact.html\)](https://www.medtronic.com/me-en/our-impact.html)

[Privacy Statement \(/me-en/privacy-statement.html\)](/me-en/privacy-statement.html) | [Terms of Use \(/me-en/terms-of-use.html\)](/me-en/terms-of-use.html)  
| [Contact \(https://www.medtronic.com/me-en/about/contact-us.html\)](https://www.medtronic.com/me-en/about/contact-us.html)

---

**UC201804678a EE** Last Updated June 2022 © 2022 Medtronic